Remove Coronary Artery Disease Remove Ischemia Remove Peripheral Arterial Disease
article thumbnail

New Guidelines on Peripheral Artery Disease Issued by American Heart Association, American College of Cardiology and Leading Medical Societies

DAIC

A new joint guideline from the American Heart Association (AHA), the American College of Cardiology (ACC) and nine other medical societies reports early diagnosis and treatment of peripheral artery disease is essential to improve outcomes and reduce amputation risk, heart attack, stroke and death for people with Peripheral Artery Disease (PAD).

article thumbnail

Elixir Medical Receives FDA Breakthrough Device Designation for DynamX BTK System for Below-The-Knee Arterial Disease

DAIC

Food and Drug Administration (FDA) for its DynamX BTK System, a novel, adaptive implant for use in the treatment of narrowed or blocked vessels below-the-knee (BTK) in patients with chronic limb-threatening ischemia (CLTI). Peripheral arterial disease ( PAD ) affects more than 200 million people worldwide. Glob Heart.

article thumbnail

HeartFlow Announces Revolutionary Five-Year Data Demonstrating a 63 Percent Mortality Reduction with FFRCT-Guided Care in PAD Patients

DAIC

1 Atherosclerosis is a systemic disease that affects multiple vascular regions and is particularly severe in PAD patients, where up to 80 percent suffer from concurrent coronary artery disease (CAD), historically linked with a mortality rate exceeding 50 percent within five years. Journal of Vascular Surgery, Mar.

article thumbnail

FFRCT Slashes PAD + CAD Mortality

CardiacWire

A study in the Journal of Vascular Surgery revealed that adding FFRCT assessments to patient workups prior to peripheral artery disease surgeries has a massive impact on coronary artery disease detection, treatments, and long-term outcomes.

article thumbnail

FDA Breakthrough Device Designation for Biotronik Freesolve Below-the-Knee Resorbable Magnesium Scaffold (RMS)

DAIC

The Freesolve BTK RMS is designed for individuals suffering from chronic limb-threatening ischemia (CLTI). CLTI is the most severe form of peripheral arterial disease (PAD), estimated to affect 11% of the 200 million people suffering from PAD globally. Jörg Pochert, President of Vascular Intervention at Biotronik.

article thumbnail

Lowering Atherosclerotic Cardiovascular Disease Events by Treating Residual Inflammatory Risk

DAIC

Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3

article thumbnail

Rise of the Lysenkoist Cardiologists

Dr. Anish Koka

Diamond and Forrester accomplished this by first establishing the prevalence of coronary artery disease based on how clinically likely patients with chest pain symptoms were found to have coronary disease based on a coronary angiogram. years of age, P <0.001), cerebral or peripheral artery disease (6.2%